Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
OBJECTIVE
To search for genetic factors in the protease and gag regions (NC-p1/TFP-p6/p6pol) involved in selection of darunavir resistance mutations.


METHODS
We analysed 48 protease inhibitor (PI)-experienced HIV-infected patients experiencing darunavir treatment failure. Viral genotyping at baseline and months 3 and 6 was used to assess the selection of mutations in the protease and gag regions conferring resistance to PIs.


RESULTS
There were no genotypic differences in the studied gag region between baseline and the latest available rebound isolates. There was an association between the presence of the mutation A431V in the gag sequence and the selection of the L76V mutation in the protease sequence in the latest available rebound. The I437T/V mutation in gag and the L76V mutation in the protease were associated with a lower risk of selecting darunavir resistance mutations.


CONCLUSIONS
In these PI-treated patients experiencing treatment failure of a darunavir-containing regimen, we showed that mutations in the gag region NC-p1/TFP-p6/p6pol may influence the selection of darunavir resistance mutations; in particular, the I437T/V gag mutation that confers resistance to PIs reduces the selection of such mutations. Virus with L76V in protease or I437T/V in gag may be already resistant to darunavir and, therefore, no additional resistance mutations need to be selected.
Lambert-Niclot
Sidonie
S
UPMC Univ Paris 06, EA 2387, F-75005, Paris, France. sidonie.lambert@psl.aphp.fr
Flandre
Philippe
P
Malet
Isabelle
I
Canestri
Ana
A
Soulié
Cathia
C
Tubiana
Roland
R
Brunet
Christel
C
Wirden
Marc
M
Katlama
Christine
C
Calvez
Vincent
V
Marcelin
Anne-Geneviève
AG